Information Collection Request

Adverse Experience/Events with Approved New Animal Drugs

ICR 202512-0910-008 · OMB 0910-0284 · Received in OIRA

Forms and Documents
IC Document Collections
IC IDCollectionTypeStatusForm
37624 Animal Drug Adverse Event Information Collection Activities Form and Instruction ModifiedVETERINARY ADVERSE DRUG REACTION, LACK OF EFFECTIVENESS, PRODUCT DEFECT REPORT (VOLUNTARY)
37624 Animal Drug Adverse Event Information Collection Activities Form and Instruction ModifiedTransmittal of Periodic Reports and Promotional Material for New Animal Drugs
37624 Animal Drug Adverse Event Information Collection Activities Form and Instruction ModifiedVETERINARY ADVERSE DRUG REACTION, LACK OF EFFECTIVENESS, PRODUCT DEFECT REPORT
197284 Recordkeeping requirements under 510.301 and 514.80 Modified
ICR Details
0910-0284 202512-0910-008
Received in OIRA 202306-0910-009
HHS/FDA CVM
Adverse Experience/Events with Approved New Animal Drugs
Revision of a currently approved collection   No
Regular 05/26/2026
  Requested Previously Approved
36 Months From Approved 08/31/2026
264,004 248,888
1,936,481 1,914,412
0 0

This information collection supports statutory and regulatory requirements governing reporting associated with certain animal drug products. With regard to adverse events and product/manufacturing defects associated with approved new animal drugs, section 512(l) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360b(l)) requires applicants with approved new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) to establish and maintain records and reports of data relating to experience with uses of such drug, or with respect to animal feeds bearing or containing such drug, to facilitate a determination under section 512(e) as to whether there may be grounds for suspending or withdrawing approval of the NADA or ANADA under section 512(e) or 512(m)(4). Regulations in § 514.80 (21 CFR 514.80) require the electronic submission of postmarketing safety reports for approved new animal drugs but provide a procedure for requesting a temporary waiver from the requirement. Respondents are those submitting adverse experience reports consistent with the applicable laws and regulations.

US Code: 21 USC 301 et seq. Name of Law: Federal Food, Drug, and Cosmetic Act
  
None

Not associated with rulemaking

  91 FR 8245 02/20/2026
91 FR 29966 05/21/2026
No

  Total Request Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 264,004 248,888 0 0 15,116 0
Annual Time Burden (Hours) 1,936,481 1,914,412 0 0 22,069 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No

$3,000,000
No
    No
    No
No
No
No
No
Kelly Covington 240 402-5661 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
05/26/2026